The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem Therapeutics; Autem therapeutics; BeOne therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeOne therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
William Chapin
Consulting or Advisory Role - GlaxoSmithKline; Merus; Replimune
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst); Merck (Inst); Merus (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Colorectal Cancer Alliance; DAVA Oncology
 
Kevin Kim
Research Funding - AstraZeneca (Inst); Hoosier Foundation (Inst); Koo Foundation (Inst); Replimune (Inst); TraSalus Life Sciences (Inst)
 
Renuka Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Incyte; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - AstraZeneca; Genentech; Replimune
 
Robert Martin
Consulting or Advisory Role - AngioDynamics
Travel, Accommodations, Expenses - AngioDynamics
 
Axel Grothey
Honoraria - Cardinal Health; Total Health Conferencing
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Daiichi Sankyo (Inst); Guardant Health (Inst); Lilly (Inst); Natera (Inst); OBI Pharma; Replimune (Inst)
Research Funding - Caris Life Sciences (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Guardant Health (Inst); Lilly (Inst); Natera (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Cardinal Health; Total Health Conferencing
 
Saikrishna Gadde
Honoraria - Exelixis
Consulting or Advisory Role - Taiho Oncology
 
Lynn Feun
Research Funding - Merck Sharp & Dohme (Inst)
 
Afshin Gabayan
No Relationships to Disclose
 
Yvonne Saenger
Consulting or Advisory Role - Regeneron
Research Funding - Nextpoint Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent for a gene signature for melanoma prognosis
 
Maen Abdelrahim
Consulting or Advisory Role - AstraZeneca; Ipsen
 
Nalini Govada
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Ben Xie
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
May Cho
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Adam Burgoyne
Consulting or Advisory Role - AstraZeneca; Deciphera; Eisai; Exelixis; Genentech/Roche; Guerbet
Speakers' Bureau - AstraZeneca; Deciphera; France Foundation
Research Funding - Alnylam (Inst); AstraZeneca (Inst); Boston Scientific (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); InhibRx (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Merck (Inst); Replimune (Inst); Taiho Oncology (Inst); Tyardi Therapeutics (Inst)